TY  - JOUR
AU  - Haroun, Michelyne
AU  - Tratrat, Christophe
AU  - Kolokotroni, Aggeliki
AU  - Petrou, Anthi
AU  - Geronikaki, Athina
AU  - Ivanov, Marija
AU  - Kostić, Marina
AU  - Soković, Marina
AU  - Carazo, Alejandro
AU  - Mladěnka, Přemysl
AU  - Sreeharsha, Nagaraja
AU  - Venugopala, Katharigatta N.
AU  - Nair, Anroop B.
AU  - Elsewedy, Heba S.
PY  - 2021
UR  - https://www.mdpi.com/2079-6382/10/3/309
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4196
AB  - In this study, we report the design, synthesis, computational and experimental evaluation of the antimicrobial activity, as well as docking studies of new 5-methylthiazole based thiazolidinones. All compounds demonstrated antibacterial efficacy, some of which (1, 4, 10 and 13) exhibited good activity against E. coli and B. cereus. The evaluation of antibacterial activity against three resistant strains, MRSA, P. aeruginosa and E. coli, revealed that compound 12 showed the best activity, higher than reference drugs ampicillin and streptomycin, which were inactive or exhibited only bacteriostatic activity against MRSA, respectively. Ten out of fifteen compounds demonstrated higher potency than reference drugs against a resistant strain of E. coli, which appeared to be the most sensitive species to our compounds. Compounds 8, 13 and 14 applied in a concentration equal to MIC reduced P. aeruginosa biofilm formation by more than 50%. All compounds displayed antifungal activity, with compound 10 being the most active. The majority of compounds showed better activity than ketoconazole against almost all fungal strains. In order to elucidate the mechanism of antibacterial and antifungal activities, molecular docking studies on E. coli Mur B and C. albicans CYP51 and dihydrofolate reductase were performed. Docking analysis of E. coli MurB indicated a probable involvement of MurB inhibition in the antibacterial mechanism of tested compounds while docking to 14α-lanosterol demethylase (CYP51) and tetrahydrofolate reductase of Candida albicans suggested that probable involvement of inhibition of CYP51 reductase in the antifungal activity of the compounds. Potential toxicity toward human cells is also reported.
PB  - MDPI AG
T2  - Antibiotics
T1  - 5-Benzyliden-2-(5-methylthiazol-2-ylimino)thiazolidin-4-ones as Antimicrobial Agents. Design, Synthesis, Biological Evaluation and Molecular Docking Studies
IS  - 3
VL  - 10
DO  - 10.3390/antibiotics10030309
SP  - 309
ER  - 

@article{
author = "Haroun, Michelyne and Tratrat, Christophe and Kolokotroni, Aggeliki and Petrou, Anthi and Geronikaki, Athina and Ivanov, Marija and Kostić, Marina and Soković, Marina and Carazo, Alejandro and Mladěnka, Přemysl and Sreeharsha, Nagaraja and Venugopala, Katharigatta N. and Nair, Anroop B. and Elsewedy, Heba S.",
year = "2021",
abstract = "In this study, we report the design, synthesis, computational and experimental evaluation of the antimicrobial activity, as well as docking studies of new 5-methylthiazole based thiazolidinones. All compounds demonstrated antibacterial efficacy, some of which (1, 4, 10 and 13) exhibited good activity against E. coli and B. cereus. The evaluation of antibacterial activity against three resistant strains, MRSA, P. aeruginosa and E. coli, revealed that compound 12 showed the best activity, higher than reference drugs ampicillin and streptomycin, which were inactive or exhibited only bacteriostatic activity against MRSA, respectively. Ten out of fifteen compounds demonstrated higher potency than reference drugs against a resistant strain of E. coli, which appeared to be the most sensitive species to our compounds. Compounds 8, 13 and 14 applied in a concentration equal to MIC reduced P. aeruginosa biofilm formation by more than 50%. All compounds displayed antifungal activity, with compound 10 being the most active. The majority of compounds showed better activity than ketoconazole against almost all fungal strains. In order to elucidate the mechanism of antibacterial and antifungal activities, molecular docking studies on E. coli Mur B and C. albicans CYP51 and dihydrofolate reductase were performed. Docking analysis of E. coli MurB indicated a probable involvement of MurB inhibition in the antibacterial mechanism of tested compounds while docking to 14α-lanosterol demethylase (CYP51) and tetrahydrofolate reductase of Candida albicans suggested that probable involvement of inhibition of CYP51 reductase in the antifungal activity of the compounds. Potential toxicity toward human cells is also reported.",
publisher = "MDPI AG",
journal = "Antibiotics",
title = "5-Benzyliden-2-(5-methylthiazol-2-ylimino)thiazolidin-4-ones as Antimicrobial Agents. Design, Synthesis, Biological Evaluation and Molecular Docking Studies",
number = "3",
volume = "10",
doi = "10.3390/antibiotics10030309",
pages = "309"
}

Haroun, M., Tratrat, C., Kolokotroni, A., Petrou, A., Geronikaki, A., Ivanov, M., Kostić, M., Soković, M., Carazo, A., Mladěnka, P., Sreeharsha, N., Venugopala, K. N., Nair, A. B.,& Elsewedy, H. S.. (2021). 5-Benzyliden-2-(5-methylthiazol-2-ylimino)thiazolidin-4-ones as Antimicrobial Agents. Design, Synthesis, Biological Evaluation and Molecular Docking Studies. in Antibiotics
MDPI AG., 10(3), 309.
https://doi.org/10.3390/antibiotics10030309

Haroun M, Tratrat C, Kolokotroni A, Petrou A, Geronikaki A, Ivanov M, Kostić M, Soković M, Carazo A, Mladěnka P, Sreeharsha N, Venugopala KN, Nair AB, Elsewedy HS. 5-Benzyliden-2-(5-methylthiazol-2-ylimino)thiazolidin-4-ones as Antimicrobial Agents. Design, Synthesis, Biological Evaluation and Molecular Docking Studies. in Antibiotics. 2021;10(3):309.
doi:10.3390/antibiotics10030309 .

Haroun, Michelyne, Tratrat, Christophe, Kolokotroni, Aggeliki, Petrou, Anthi, Geronikaki, Athina, Ivanov, Marija, Kostić, Marina, Soković, Marina, Carazo, Alejandro, Mladěnka, Přemysl, Sreeharsha, Nagaraja, Venugopala, Katharigatta N., Nair, Anroop B., Elsewedy, Heba S., "5-Benzyliden-2-(5-methylthiazol-2-ylimino)thiazolidin-4-ones as Antimicrobial Agents. Design, Synthesis, Biological Evaluation and Molecular Docking Studies" in Antibiotics, 10, no. 3 (2021):309,
https://doi.org/10.3390/antibiotics10030309 . .

TY  - JOUR
AU  - Tratrat, Christophe
AU  - Haroun, Michelyne
AU  - Xenikakis, Iakovos
AU  - Liaras, Konstantinos
AU  - Tsolaki, Evangelia
AU  - Eleftheriou, Phaedra
AU  - Petrou, Anthi
AU  - Aldhubiab, Bandar
AU  - Attimarad, Mahesh
AU  - Venugopala, Katharigatta N.
AU  - Harsha, Sree
AU  - Elsewedy, Heba S.
AU  - Geronikaki, Athina
AU  - Soković, Marina
PY  - 2019
UR  - http://www.eurekaselect.com/169442/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3358
AB  - BACKGROUND Thiazole derivates as well as chalcones, are very important scaffold for medicinal chemistry. Literature survey revealed that they possess wide spectrum of biological activities among which are anti-inflammatory and antimicrobial. OBJECTIVES The current studies describe the synthesis and evaluation of antimicrobial activity of twenty eight novel thiazole-based chalcones. METHODS The designed compounds were synthesized using classical methods of organic synthesis. The in vivo evaluation of antimicrobial activity was performed by microdilution method. RESULTS All compounds have shown antibacterial properties better than that of ampicillin and in many cases better than streptomycin. As far as the antifungal activity is concerned, all compounds possess much higher activity than reference drugs bifonazole and ketoconazole. The most sensitive bacterial species was B. cereus (MIC 6.5-28.4 µmol × 10-2/mL and MBC 14.2-105.0 µmol × 10-2/mL) while the most resistant ones were L. monocytogenes (MIC 21.4-113.6 µmol × 10-2/mL) and E. coli (MIC 10.7- 113.6 µmol × 10-2/mL) and MBC at 42.7-358.6 µmol × 10-2/mL and 21.4-247.2 µmol × 10-2/mL, respectively. All the compounds exhibited antibacterial activity against the three resistant strains, MRSA, P. aeruginosa and E.coli. with MIC and MBC in the range of 0.65-11.00 µmol/mL × 10-2 and 1.30-16.50 µmol/mL × 10-2. Docking studies were performed. CONCLUSION Twenty-eight novel thiazole-based chalcones were designed, synthesized and evaluated for antimicrobial activity. The results showed that these derivatives could be lead compounds in search of new potent antimicrobial agents. Docking studies indicated that DNA gyrase, GyrB and MurA inhibition may explain the antibacterial activity.
T2  - Current Topics in Medicinal Chemistry
T1  - Design, Synthesis, Evaluation of Antimicrobial Activity and Docking Studies of New Thiazole-based Chalcones.
IS  - 5
VL  - 19
DO  - 10.2174/1568026619666190129121933
SP  - 356
EP  - 375
ER  - 

@article{
author = "Tratrat, Christophe and Haroun, Michelyne and Xenikakis, Iakovos and Liaras, Konstantinos and Tsolaki, Evangelia and Eleftheriou, Phaedra and Petrou, Anthi and Aldhubiab, Bandar and Attimarad, Mahesh and Venugopala, Katharigatta N. and Harsha, Sree and Elsewedy, Heba S. and Geronikaki, Athina and Soković, Marina",
year = "2019",
abstract = "BACKGROUND Thiazole derivates as well as chalcones, are very important scaffold for medicinal chemistry. Literature survey revealed that they possess wide spectrum of biological activities among which are anti-inflammatory and antimicrobial. OBJECTIVES The current studies describe the synthesis and evaluation of antimicrobial activity of twenty eight novel thiazole-based chalcones. METHODS The designed compounds were synthesized using classical methods of organic synthesis. The in vivo evaluation of antimicrobial activity was performed by microdilution method. RESULTS All compounds have shown antibacterial properties better than that of ampicillin and in many cases better than streptomycin. As far as the antifungal activity is concerned, all compounds possess much higher activity than reference drugs bifonazole and ketoconazole. The most sensitive bacterial species was B. cereus (MIC 6.5-28.4 µmol × 10-2/mL and MBC 14.2-105.0 µmol × 10-2/mL) while the most resistant ones were L. monocytogenes (MIC 21.4-113.6 µmol × 10-2/mL) and E. coli (MIC 10.7- 113.6 µmol × 10-2/mL) and MBC at 42.7-358.6 µmol × 10-2/mL and 21.4-247.2 µmol × 10-2/mL, respectively. All the compounds exhibited antibacterial activity against the three resistant strains, MRSA, P. aeruginosa and E.coli. with MIC and MBC in the range of 0.65-11.00 µmol/mL × 10-2 and 1.30-16.50 µmol/mL × 10-2. Docking studies were performed. CONCLUSION Twenty-eight novel thiazole-based chalcones were designed, synthesized and evaluated for antimicrobial activity. The results showed that these derivatives could be lead compounds in search of new potent antimicrobial agents. Docking studies indicated that DNA gyrase, GyrB and MurA inhibition may explain the antibacterial activity.",
journal = "Current Topics in Medicinal Chemistry",
title = "Design, Synthesis, Evaluation of Antimicrobial Activity and Docking Studies of New Thiazole-based Chalcones.",
number = "5",
volume = "19",
doi = "10.2174/1568026619666190129121933",
pages = "356-375"
}

Tratrat, C., Haroun, M., Xenikakis, I., Liaras, K., Tsolaki, E., Eleftheriou, P., Petrou, A., Aldhubiab, B., Attimarad, M., Venugopala, K. N., Harsha, S., Elsewedy, H. S., Geronikaki, A.,& Soković, M.. (2019). Design, Synthesis, Evaluation of Antimicrobial Activity and Docking Studies of New Thiazole-based Chalcones.. in Current Topics in Medicinal Chemistry, 19(5), 356-375.
https://doi.org/10.2174/1568026619666190129121933

Tratrat C, Haroun M, Xenikakis I, Liaras K, Tsolaki E, Eleftheriou P, Petrou A, Aldhubiab B, Attimarad M, Venugopala KN, Harsha S, Elsewedy HS, Geronikaki A, Soković M. Design, Synthesis, Evaluation of Antimicrobial Activity and Docking Studies of New Thiazole-based Chalcones.. in Current Topics in Medicinal Chemistry. 2019;19(5):356-375.
doi:10.2174/1568026619666190129121933 .

Tratrat, Christophe, Haroun, Michelyne, Xenikakis, Iakovos, Liaras, Konstantinos, Tsolaki, Evangelia, Eleftheriou, Phaedra, Petrou, Anthi, Aldhubiab, Bandar, Attimarad, Mahesh, Venugopala, Katharigatta N., Harsha, Sree, Elsewedy, Heba S., Geronikaki, Athina, Soković, Marina, "Design, Synthesis, Evaluation of Antimicrobial Activity and Docking Studies of New Thiazole-based Chalcones." in Current Topics in Medicinal Chemistry, 19, no. 5 (2019):356-375,
https://doi.org/10.2174/1568026619666190129121933 . .

TY  - JOUR
AU  - Haroun, Michelyne
AU  - Tratrat, Christophe
AU  - Kositsi, Katerina
AU  - Tsolaki, Evangelia
AU  - Petrou, Anthi
AU  - Aldhubiab, Bandar
AU  - Attimarad, Mahesh
AU  - Harsha, Sree
AU  - Geronikaki, Athina
AU  - Venugopala, Katharigatta N.
AU  - Elsewedy, Heba S.
AU  - Soković, Marina
AU  - Glamočlija, Jasmina
AU  - Ćirić, Ana
PY  - 2018
UR  - http://www.eurekaselect.com/159582/article
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3071
AB  - BACKGROUND Thiazole and benzothiazole derivatives, as well as thiazolidinones are very important scaffolds in medicinal chemistry. Literature has revealed that they possess a wide spectrum of biological activities including antimicrobial activity. OBJECTIVE The goal of this paper is the designing of new benzothiazole based thiazolidinones and the evaluation of their biological activities. METHODS The designed compounds were synthesized using classical organic synthesis methods. The antimicrobial activity was evaluated using the method of microdilution. RESULTS The twelve newly synthesized compounds showed antimicrobial properties. All compounds appeared to be more active than ampicillin in most studied strains and in some cases, more active than streptomycin. Antifungal activity, in most cases was also better than the reference drugs ketoconazole and bifonazole. The prediction of cytotoxicity revealed that the synthesized compounds were not toxic (LD50 350-1000 mg/kg of body weight). Docking studies on the antibacterial activity confirmed the biological results. CONCLUSION The twelve new compounds were synthesized and studied for their antimicrobial activity. The compounds appeared to be promising antimicrobial agents and could be the lead compounds for new, more potent drugs. According to the docking prediction, the compounds could be MurB inhibitors.
T2  - Current Topics in Medicinal Chemistry
T1  - New Benzothiazole-based Thiazolidinones as Potent Antimicrobial Agents. Design, synthesis and Biological Evaluation.
IS  - 1
VL  - 18
DO  - 10.2174/1568026618666180206101814
SP  - 75
EP  - 87
ER  - 

@article{
author = "Haroun, Michelyne and Tratrat, Christophe and Kositsi, Katerina and Tsolaki, Evangelia and Petrou, Anthi and Aldhubiab, Bandar and Attimarad, Mahesh and Harsha, Sree and Geronikaki, Athina and Venugopala, Katharigatta N. and Elsewedy, Heba S. and Soković, Marina and Glamočlija, Jasmina and Ćirić, Ana",
year = "2018",
abstract = "BACKGROUND Thiazole and benzothiazole derivatives, as well as thiazolidinones are very important scaffolds in medicinal chemistry. Literature has revealed that they possess a wide spectrum of biological activities including antimicrobial activity. OBJECTIVE The goal of this paper is the designing of new benzothiazole based thiazolidinones and the evaluation of their biological activities. METHODS The designed compounds were synthesized using classical organic synthesis methods. The antimicrobial activity was evaluated using the method of microdilution. RESULTS The twelve newly synthesized compounds showed antimicrobial properties. All compounds appeared to be more active than ampicillin in most studied strains and in some cases, more active than streptomycin. Antifungal activity, in most cases was also better than the reference drugs ketoconazole and bifonazole. The prediction of cytotoxicity revealed that the synthesized compounds were not toxic (LD50 350-1000 mg/kg of body weight). Docking studies on the antibacterial activity confirmed the biological results. CONCLUSION The twelve new compounds were synthesized and studied for their antimicrobial activity. The compounds appeared to be promising antimicrobial agents and could be the lead compounds for new, more potent drugs. According to the docking prediction, the compounds could be MurB inhibitors.",
journal = "Current Topics in Medicinal Chemistry",
title = "New Benzothiazole-based Thiazolidinones as Potent Antimicrobial Agents. Design, synthesis and Biological Evaluation.",
number = "1",
volume = "18",
doi = "10.2174/1568026618666180206101814",
pages = "75-87"
}

Haroun, M., Tratrat, C., Kositsi, K., Tsolaki, E., Petrou, A., Aldhubiab, B., Attimarad, M., Harsha, S., Geronikaki, A., Venugopala, K. N., Elsewedy, H. S., Soković, M., Glamočlija, J.,& Ćirić, A.. (2018). New Benzothiazole-based Thiazolidinones as Potent Antimicrobial Agents. Design, synthesis and Biological Evaluation.. in Current Topics in Medicinal Chemistry, 18(1), 75-87.
https://doi.org/10.2174/1568026618666180206101814

Haroun M, Tratrat C, Kositsi K, Tsolaki E, Petrou A, Aldhubiab B, Attimarad M, Harsha S, Geronikaki A, Venugopala KN, Elsewedy HS, Soković M, Glamočlija J, Ćirić A. New Benzothiazole-based Thiazolidinones as Potent Antimicrobial Agents. Design, synthesis and Biological Evaluation.. in Current Topics in Medicinal Chemistry. 2018;18(1):75-87.
doi:10.2174/1568026618666180206101814 .

Haroun, Michelyne, Tratrat, Christophe, Kositsi, Katerina, Tsolaki, Evangelia, Petrou, Anthi, Aldhubiab, Bandar, Attimarad, Mahesh, Harsha, Sree, Geronikaki, Athina, Venugopala, Katharigatta N., Elsewedy, Heba S., Soković, Marina, Glamočlija, Jasmina, Ćirić, Ana, "New Benzothiazole-based Thiazolidinones as Potent Antimicrobial Agents. Design, synthesis and Biological Evaluation." in Current Topics in Medicinal Chemistry, 18, no. 1 (2018):75-87,
https://doi.org/10.2174/1568026618666180206101814 . .